Ciprofloxacin-resistant Pseudomonas keratitis

Ophthalmology

Volumn 106, Issue 7, 1999, Pages 1319-1323

  Garg, Prashant ^a,b   Sharma, Savitri ^b   Rao, Gullapalli N ^a  

^a Sight Savers' Corneal Train Centre   (India)

^b L V PRASAD EYE INSTITUTE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CEFAZOLIN; CHLORAMPHENICOL; CIPROFLOXACIN; GENTAMICIN; NORFLOXACIN;

ADOLESCENT; ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CHILD; CLINICAL ARTICLE; EVISCERATION; FEMALE; HUMAN; IN VITRO STUDY; KERATITIS; KERATOPLASTY; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS; RETROSPECTIVE STUDY; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0033498181     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0161-6420(99)00717-4     Document Type: Article

References (30)

1. Neu HC. Microbiologic aspects of fluoroquinolones. Am J Ophthalmol 1991;112:15S-24S.
2. Neu HC. Ciprofloxacin: an overview and prospective appraisal. Am J Med 1987;82(suppl 4A):395-404.
3. Chin NX, Neu HC. Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteria. Antimicrob Agents Chemother 1984;25:319-26.
4. O'Brien TP, Sawusch MR, Dick JD, Gottsch JD. Topical ciprofloxacin treatment of Pseudomonas keratitis in rabbits. Arch Ophthalmol 1988;106:1444-6.
5. Leibowitz HM. Clinical evaluation of ciprofloxacin 0.3% ophthalmic solution for treatment of bacterial keratitis. Am J Ophthalmol 1991;112:34S-47S.
6. Parks DJ, Abrams DA, Sarfarazi FA, Katz HR. Comparison of topical ciprofloxacin to conventional antibiotic therapy in the treatment of ulcerative keratitis. Am J Ophthalmol 1993;115: 471-7.
7. Hyndiuk RA, Eiferman RA, Caldwell DR, et al. Comparison of ciprofloxacin ophthalmic solution 0.3% to fortified tobramycin-cefazolin in treating bacterial corneal ulcers. Ophthalmology 1996;103:1854-63.
8. Hooper DC, Wolfson JS, Ng EY, Swartz MN. Mechanisms of action and resistance to ciprofloxacin. Am J Med 1987; 82(suppl 4A):12-20.
9. Kaatz GW, Seo SM. Mechanism of ciprofloxacin resistance in Pseudomonas aeruginosa. J Infect Dis 1988;158:537-41.
10. Raviglione MC, Boyle JF, Mariuz P, et al. Ciprofloxacin-resistant methicillin-resistant Staphylococcus aureus in an acute-care hospital. Antimicrob Agents Chemother 1990;34: 2050-4.
11. Humphreys H, Mulvihill E. Ciprofloxacin-resistant Staphylococcus aureus [letter]. Lancet 1985;2(8451):383.
12. Ball P. Emergent resistance to ciprofloxacin among Pseudomonas aeruginosa and Staphylococcus aureus: clinical significance and therapeutic approaches. J Antimicrob Chemother 1990;26(suppl F):165-79.
13. George RC, Ball LC, Norbury PB. Susceptibility to ciprofloxacin of nosocomial gram-negative bacteria and staphylococci isolated in the UK. J Antimicrob Chemother 1990; 26(Suppl F):145-56.
14. Knauf HP, Silvany R, Southern PM Jr, et al. Susceptibility of corneal and conjunctival pathogens to ciprofloxacin. Cornea 1996;15:66-71.
15. Kunimoto DY, Sharma S, Garg P, Rao GN. In vitro susceptibility of bacterial keratitis pathogens to ciprofloxacin. Emerging resistance. Ophthalmology 1999;106:80-5.
16. Snyder ME, Katz HR. Ciprofloxacin-resistant bacterial keratitis. Am J Ophthalmol 1992;114:336-8.
17. Maffett M, O'Day DM. Ciprofloxacin-resistant bacterial keratitis [letter]. Am J Ophthalmol 1993;115:545-6.
18. Jones DB. Decision-making in the management of microbial keratitis. Ophthalmology 1981;88:814-20.
19. Leibowitz HM. Bacterial keratitis. In: Leibowitz HM and seventeen contributing authors. Corneal Disorders: Clinical Diagnosis and Management. Philadelphia: W.B. Saunders, 1984;353-86.
20. Bowe BE, Snyder JW, Eiferman RA. An in vitro study of the potency and stability of fortified ophthalmic antibiotic preparations. Am J Ophthalmol 1991;111:686-9.
21. Petroutsos G, Guimaraes Y, Pouliquen Y. The effect of concentrated antibiotics on the rabbit's corneal epithelium. Int Ophthalmol 1984;7:65-9.
22. Olson RJ. How exposed are we? Is there a better way? Arch Opthalmol 1989;107:1131.
23. Reidy JJ, Hobden JA, Hill JM, et al. The efficacy of topical ciprofloxacin and norfloxacin in the treatment of experimental Pseudomonas keratitis. Cornea 1991;10:25-8.
24. Lauffenburger MD, Cohen KL. Topical ciprofloxacin versus topical fortified antibiotics in rabbit models of Staphylococcus and Pseudomonas keratitis. Cornea 1993;12:517-21.
25. Guzek JP, Chacko D, Kettering JD, et al. Comparison of topical ciprofloxacin to conventional antibiotic therapy in the treatment of experimental Pseudomonas aeruginosa keratitis. Cornea 1994;13:500-4.
26. Wilhelmus KR, Hyndiuk RA, Caldwell DR, et al. 0.3% ciprofloxacin ophthalmic ointment in the treatment of bacterial keratitis. Arch Ophthalmol 1993;111:1210-8.
27. McLeod SD, DeBacker CM, Viana MAG. Differential care of corneal ulcers in the community based on apparent severity. Ophthalmology 1995;103:479-84.
28. Kotilainen P, Nikoskelainen J, Huovinen P. Emergence of ciprofloxacin-resistant coagulase-negative staphylococcal skin flora in immunocompromised patients receiving ciprofloxacin. J Infect Dis 1990;161:41-4.
29. Daum TE, Schaberg DR, Terpenning MS, et al. Increasing resistance of Staphylococcus aureus to ciprofloxacin. Antimicrob Agents Chemother 1990;34:1862-3.
30. Bower KS, Kowalski RP, Gordon YJ. Fluoroquinolones in the treatment of bacterial keratitis. Am J Ophthalmol 1996;121: 712-5.